natgillin/translations-raw huggingface dataset:
a light chain variable amino acid sequence of SEQ ID NO: 38 and a heavy chain variable amino acid sequence of SEQ ID NO: 33. 
(11) varijabilnu sekvencu aminokiselina laganog lanca SEQ ID NO: 38 1 varijabilnu sekvencu aminokiselina teškog lanca SEQ ID NO: 33.
wherein each Ψ is a residue independently selected from Lys, Arg, Orn and Cys and wherein the side chain of each residue Ψ is conjugated to a lipophilic substituent; 
gdje svaki Ψ predstavlja ostatak koji je neovisno odabran od Lys, Arg, Orn i Cys, te gdje je bočni lanac od svakog ostatka Ψ konjugiran na lipofilni supstituent;
A method for the treatment of a subject suffering from sepsis, systemic inflammatory response syndrome, severe sepsis, or septic shock, the method comprising: 
Heparin osiromašen s pentasaharidom naznačen time da je za uporabu u liječenju ili prevenciji sepse, sindroma sistemskog upalnog odgovora (SIRS), teške sepse ili septičkog šoka,
a light chain variable domain comprising the amino acid sequence of SEQ ID NO:9, wherein CDR1 is defined by SEQ ID NO:16, CDR2 is defined by SEQ ID NO:21, and CDR3 is defined by SEQ ID NO:22; and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:10, wherein CDR1 is defined by SEQ ID NO:23, CDR2 is defined by SEQ ID NO:14, and CDR3 is defined by SEQ ID NO:20; or 
varijabilnu domenu lakog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:9, gdje je CDR1 definiran sa SEQ ID NO:16, CDR2 je definiran sa SEQ ID NO:21, a CDR3 je definiran sa SEQ ID NO:22; i varijabilnu domenu teškog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:10, gdje je CDR1 definiran sa SEQ ID NO:23, CDR2 je definiran sa SEQ ID NO:14, a CDR3 je definiran sa SEQ ID NO:20; ili
"ester", as used herein, pertains to a -C(=O)OR group, wherein R is a C1-7 alkyl group, a C3-20 heterocyclyl group, or a C5-20 aryl group; 
"ester", kako se ovdje koristi, odnosi se na -C(=0)0R skupinu, pri čemu R je C,; alkilna skupina, C329 heterociklilna skupina, ili C5. arilna skupina;
the genetically modified host cell is in vitro or ex vivo; and/or 
genetički modificirana stanica domaćin je in vitro ili ex vivo; i/ili
A solvent composition, comprising: methyl soyate; 
Formulacija otapala, koja sadrži: metil-sojat;
The pharmacokinetic profiles of gemcitabine and a compound of formula I, are assessed in male CD-1 mice following oral administration at doses selected to contain approximately 10 mg/kg of gemcitabine. 
Farmakokinetika kod miša Farmakokinetički profili gemcitabina i spoja formule I procijenjeni su na mužjacima CD-1 miševa nakon oralne primjene u dozama koje su tako odabrane da sadrže približno 10 mg/kg gemcitabina.
The method of paragraph 7, wherein the adverse reaction is grades 3 or 4 thrombocytopenia. 
Postupak prema zahtjevu 4, pri čemu je neželjena reakcija stupanj 3 ili 4 trombocitopenije.
Hepatitis B is an infectious disease of the liver caused by the Hepatitis B virus (HBV). 
INHIBICIJA, POSREDOVANA RNA INTERFERENCIJOM, EKSPRESIJE GENA VIRUSA HEPATITISA B (HBV) KORISTENJEM KRATKIH INTERFERIRAJUĆIH NUKLEINSKIH
a prokaryotic cell, wherein the prokaryotic cell is a bacterial cell, preferably, wherein the bacterial cell is an E. coli cell; or 
prokariotska stanica, s time, da prokariotska stanica je stanica bakterije, preferirano, gdje je stanica bakterije stanica bakterije E. coli; ili
In further embodiments, the pre-fusion RSV F polypeptides comprise one or more further mutations (as compared to the wild-type RSV F protein), selected from the group consisting of: 
Prefuzijski RSV F polipeptid prema bilo kojem od zahtjeva 1-4, naznačen time što polipeptid obuhvaća najmanje jednu daljnju mutaciju, pri čemu je navedena mutacija odabrana iz skupine koja sadrži:
A combination according to any one of claims 1 to 3, wherein the B2 agonist is selected from the group comprising arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, dopexamine, fenoterol, formoterol, hexoprenaline, ibuterol, isoprenaline, levosalbutamol, mabuterol, meluadrine, nolomirole, orciprenaline, pirbuterol, procaterol, (R,R)-formoterol, reproterol, ritodrine, rimoterol, salbutamol, salmeterol, sibenadet, sulfonterol, terbutaline, tulobuterol, GSK-597901, GSK-159797,KUL-1248,TA-2005 and QAB-149, optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija prema zahtjevu 1 ili 2, naznačena time, da je 2 agonist odabran iz skupine koja sadrži arformoterol, bambuterol, bitolterol, broksaterol, karbuterol, klenbuterol, dopeksamin, fenoterol, heksoprenalin, ibuterol, izoprenalin, levosalbutamol, mabuterol, meluadrin, nolomirol, orciprenalin, pirbuterol, prokaterol, (R,R)- formoterol, reproterol, ritodrin, rimoterol, salbutamol, sibenadet, sulfonterol, terbutalin i tulobuterol, po izboru u obliku njihovih racemata, njihovih enantiomera, njihovih diastereomera i njihovih smjesa, te prema potrebi njihovih farmakološki kompatibilnih kiselinskih adicijskih soli.
The method of any one of paragraphs 1-7, wherein the plurality of liposomes comprises unilamellar vesicles, multilamellar vesicles, or a mixture thereof. 
Farmaceutski pripravak za uporabu prema patentnom zahtjevu 4, naznačen time, što liposom sadrži jednolamelarne vezikule, višelamelarne vezikule, ili njihovu mješavinu.
[Paragraph 9] The compound of paragraph 6 wherein the compound is 4-(6-hydroxyquinolin-2-yl)-3-methylbenzoic acid. 
Spoj ili sol prema zahtjevu 6, naznačen/a time, da spoj je 4-(6-hidroksikinolin-2-il)-3-metilbenzoeva kiselina.
The filter cake is then dried in an oven 60° C. overnight. 
Kolač od filtriranja je zatim zagrijavan u peći pri 60 *C preko noći.
Compound of formula I or a salts, a N-oxide or a salt of a N-oxide of this compound as chimed in any one of claim 1 to 6 for use in the treatment of diabetes mellitus. 
Spoj formule I prema zahtjevu 5, naznačen time, da se upotrebljava za liječenje mellitus dijabetesa.
In an especially preferred embodiment, the aqueous solution contains chlorine dioxide in a quantity of about 0.3 to about 1 wt %, with the pH-value of the solution being in the range of about 2 to about 4 and the solution not containing a buffer. 
Vodena otopina klorovog dioksida, naznačena time što sadrži klorov dioksid u količini u rasponu od više od 0.3 do 4.5 masenih %, te pH otopine leži u rasponu od 2 do 3 i otopina ne sadrži pufer.
Compounds of formula (111) wherein R6 is 2-hydroxyphenyl may be from the corresponding compounds of formula (111) wherein R6 is a 2-benzyloxyphenyl group by hydrogenolysis using hydrogen and a palladium catalyst. 
Spojeve formule (111), gdje Rg je 2-hidroksifenil, može se dobiti iz odgovarajućih spojeva formule (111), gdje Rs je 2-beniloksifenilna skupina, hidrogenolizom vodikom uz paladijski katalizator.
The composition of claim 1, wherein the mature human KLK1 polypeptide(s) consists of amino acid residues 25-262 of SEQ ID NO:1 or amino acid residues 25-262 of SEQ ID NO:2. 
Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što jedan ili više polipeptida KLKI1 se sastoji od aminokiselinskih ostataka 25-262 iz SEQ ID NO:1 ili aminokiselinskih ostataja 25-262 iz SEQ ID NO:2.
The process according to claim 7, wherein the crystallization is carried out in the presence of a mixture of (C1-C3)alcohol and water. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što se kristaliziranje provodi u prisutnosti smjese (C1-C3) alkohola i vode.
(a) at least 97% of the cells in the population express detectable levels of MIC A/B, 
(a) (i) najmanje 97 % stanica u populaciji na svojoj površini izražava uočljive razine MIC A/B,
In some embodiments, the ingredient comprises a mixture of a hydrophilic solvent and a lipophilic solvent. 
Formulacija prema zahtjevu 1, naznačena time, da je sastojak mješavina hidrofilnog otapala 1 lipofilnog otapala.
reacting the so obtained product of formula XII wherein X is oxygen or sulfur; 
reakciju tako dobivenog produkta s formulom XII [image] pri čemu X je kisik ili sumpor;
The nonwoven fabric of claim 18, wherein the semi-crystalline polymer of the matrix and binder components has a degree of crystallinity of at least 95%. 
Netkano predivo prema zahtjevu 22, naznačeno time, da polukristalni polimer od vlakana ima stupanj kristalnosti od najmanje 95%.
Accordingly, in a more preferred embodiment the mammalian cell is a COS cell; a BHK cell; a HEK293 cell; a CHO cell; a myeloma cell; or a MDCK cell. 
Stanica iz patentnog zahtjeva 10 pri čemu je stanica stanica sisavca ili stanica kukca, ili pri čemu je stanica stanica kvasca, poželjno Saccharomyces cerevisiae, Schizosaccharomyces pombe, ili Pichia pastoris.
In one or a further embodiment, step a) comprises adding a metal chelating agent, such as EDTA, EGTA or citric acid. 
Postupak in vitro prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da korak a) obuhvaća dodavanje kelatnog sredstva za metal, kao što je EDTA, EGTA ili limunska kiselina.
The anti-cancer composition for use according to claim 1, wherein the composition comprises one or two additional sugars alcohols. 
Pripravak protiv raka za uporabu prema zahtjevu 1, naznačen time da pripravak sadrži one ili dva dodatna šećerna alkohola.
the second binding domain is capable of binding to CD3; and wherein epitope cluster 3 of BCMA corresponds to amino acid residues 24 to 41 of the sequence as depicted in SEQ ID NO: 1002, and epitope cluster 4 of BCMA corresponds to amino acid residues 42 to 54 of the sequence as depicted in SEQ ID NO: 1002. 
(b) druga vezujuća domena sposobna je za vezanje na CD3; i pri čemu epitop klastera 3 od BCMA odgovara ostatcima aminokiseline 24 do 41 od sekvence kao što je prikazano u SEQ ID NO: 1002, i pri čemu je navedena vezujuća molekula polipeptid.
at least for a fraction of the socket forming time the process air, maintained at the socket forming pressure, pressing the end (20) of the pipe (2) onto the outer lateral walls (130) of the forming mandrel (13). The forming method according to claim 14, characterised in that: 
- <- barem tijekom dijela vremena formiranja čahure zrak za postupak, koji se održava na pritisku za formiranje čahure, pritišće završetak (20) cijevi (2) prema vanjskim bočnim stjenkama (130) roga za oblikovanje (13).
A suspension according to claim 7, characterized in that said surfactant is selected from sodium lauryl sulphate, dioctyl sodium sulfosuccinate, cetylpyridinium chloride, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, polyoxyethylene fatty ethers, polyoxyethylene stearates and/or poloxamers. 
Suspenzija u skladu s patentnim zahtjevom 1, naznačena time što se navedeni surfaktant bira između natrijevog lauril-sulfata, dioktil natrijevog sulfosukcinata (natrijevog dokusata), polioksietileniranog ricinusovog ulja, polioksietileniranih masnih etera i/ili poloksamera.
Detailed description of the invention This invention provides a microfluidic device and method for determining clotting time of a fluid, such as blood. 
Mikrofluidički uređaj određivanja vremena koagulacije u fluidnom mediju, poput krvi ili plazme, gdje se navedeni uređaj sastoji od
Suitable short extension linkers can be 5 to 20 amino acid residues in length. The short extension linker can also be about 10 amino acids in length. 
Postupak prema zahtjevu 1 ili 2 naznačen time da kratka proširujuća poveznica sadrži 5 do 20 ostataka aminokiselina.
from 0% to 10%, or from 0% to 6% (w/v) of a isotonizing agent 
(d) od 0% do 10 %, ili od 0% do 6% (w/v) izotoničkog sredstva
wherein contact time from the beginning of step (b) to the beginning of step (c) is less than 60 minutes. 
pri čemu vrijeme kontakta od početka koraka (a) do početka koraka (b) iznosi manje od 15 minuta.
Also preferred is an extended release tablet formulation, wherein the substantially neutral polymer is selected from hydroxypropylcellulose and hydroxypropylmethylcellulose. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 4, naznačena time, da u biti neutralan polimer je izabran između hidroksipropilceluloze i hidroksipropilmetilceluloze.
A metered dose inhaler according to claim 14, wherein the metered dose inhaler dispenses the co-suspension at an initial fine particle fraction and the initial fine particle fraction dispensed from the metered dose inhaler is substantially maintained, such that, throughout emptying of the canister, the fine particle fraction delivered from the metered dose inhaler is maintained within 80% of the initial fine particle fraction, within 90% of the initial fine particle fraction or within 95% of the initial fine particle fraction. 
Inhalator za odmjerene doze u skladu s patentnim zahtjevom 14, naznačen time što inhalator za odmjerene doze izdaje ko-suspenziju u početnoj frakciji finih čestica, gdje se početnu frakciju finih čestica izdanu iz inhalatora za odmjerene doze uglavnom održava, tako da se, tijekom pražnjenja spremnika, frakciju finih čestica unesena iz inhalatora za odmjerene doze održava unutar 80% od početne frakcije finih čestica, unutar 90% od početne frakcije HR P20161098 T1 finih čestica ili unutar 95% od početne frakcije finih čestica.
Further, it has to be considered that, in the context of the present invention, the veneers are cut, however not sawn or otherwise formed in a fiber removing (machining) process. 
Nadalje, treba uzeti u obzir da se, u vezi s predmetnim izumom, furniri režu, ali se ne pile ili drukčije oblikuju u postupku uklanjanja (strojne obrade) vlakana.
The method of claim 18 wherein the virus is selected from the group consisting of dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus. 
Tvar za uporabu u skladu s patentnim zahtjevom 7 pri čemu je virus odabran iz grupe koja se sastoji od dengue virusa, virusa žute groznice, West Nile virusa, virusa japanskog encefalitisa, virusa krpeljnog encefalitisa, virusa Kunjin, virusa Murray Valley encefalitisa, virusa St. Louis encefalitisa, virusa Omsk hemoragične groznice, virusa goveđe virusne dijareje, Zika virusa 1 virusa hepatitisa C.
A pharmaceutical composition comprising the crystalline molecular complex of claim 1 and a pharmaceutically acceptable excipient. 
Molekularni kompleks koji se bira iz skupine koja sadrži: kompleks kristalne zoledronske kiseline, vode, i L-lizina;
Alternatively, step (b) may be performed with Purified Water. 
Alternativno, korak (b) se može provoditi i s pročišćenom vodom.
After 1 hour and 40 minutes, reaction is added to 25 mL water and extracted with EtOAc. 
Nakon 1 sata i 40 minuta, reakcijsku smjesu se doda u 25 ml vodo i ekstrahira se s EtOAc.
The antibody or antigen-binding fragment thereof of claim 5, wherein the brain targeting moiety is selected from the group consisting of the single domain antibody FC5, the monoclonal antibody mAB 83-14 to the human insulin receptor, a B2 peptide that binds to the human transferrin receptor, a B6 peptide that binds to the human transferrin receptor, and a B8 peptide that binds to the human transferrin receptor, anti-Fc receptor, transferrin, and anti-insulin receptor. 
Protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 5, naznačeno time što se ostatak koji cilja na mozak bira iz skupine koju čine jednodomensko protutijelo FC5, monoklonsko protutijelo mAB 83-14 protiv receptora ljudskog inzulina, peptid B2 koji se veže na receptor ljudskog transferina, peptid B6 koji se veže na receptor ljudskog transferina, zatim peptid BS koji se veže na receptor ljudskog transferina, anti-Fc receptor, transferin, te antiinzulinski receptor.
A pharmaceutical composition for inhibiting expression of a TTR gene comprising the dsRNA of any one of claims 1 to 11 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak za inhibiranje ekspresije TTR gena koji je naznačen time da sadrži dsRNA prema zahtjevima 1 do 8 i farmaceutski prihvatljiv nosač.
the glucuronide that can be cleaved by B-glucuronidase is and wherein the antibody is a monoclonal antibody, a target binding antibody fragment, a single chain Fv (scFv) mutant, a multispecific antibody, a bispecific antibody generated from at least two intact antibodies, a chimeric antibody, a humanized antibody, or a human antibody, or a fusion protein comprising a target binding antibody fragment. 
A 07% >NH, IZ i glukuronid koji se može cijepati s B-glukuronidazom je i pri čemu je antitijelo monoklonsko antitijelo, fragment ciljnog vezivnog antitijela, jednolančani Fv(scFv) mutant, multispecifično antitijelo, bispecifično antitijelo koje se proizvodi od najmanje dva intaktna antitijela,
The use according to claim 6, wherein the disease to be treated is selected from proliferative disease. 
70 i/ili JGF-IR, pri čemu se bolest koja se treba liječiti odabire od proliferativnih bolesti.
inhibits or reduces artemin-sensitized thermal hyperalgesia in vivo; 
(vi) inhibira ili smanjuje termalnu hiperalgeziju aktiviranu arteminom in vivo;
the high ethanol concentration is 24%, 
- < koncentracija višeg etanola je 24%,
The compound according to claim 1, wherein the R1 group of formula (I) is in a 4S configuration. 
Spoj prema zahtjevu 1, naznačen time, što se R' grupa formule (1) nalazi u 4S konfiguraciji.
hum13B8 LC DNA A purified binding compound that binds to human IL-23, comprising: an antibody light chain variable domain, or antigen binding fragment thereof, comprising CDRL1, CDRL2 and CDRL3, wherein: 
Antitijelo ili antigen-vežući fragment istog koji se veže za humani IL-23, naznačeno time, što sadrži: a) varijabilnu domenu lakog lanca, ili antigen-vežući fragment istog, koja sadrži CDRLI, CDRL2 i CDRL3, pri čemu:
The presence of oligofructose is necessary for certain applications such as baked products in which a brown colouring is required. 
Prisutnost oligofruktoze nužna je u nekim oblicima primjene, npr. u pečenih proizvoda u kojih se traži postizanje smeđe boje.
As a result of the rapid and reliable connection of the pressure line to, on the one hand, the CO2 cartridge and, on the other hand, the drink chamber when the lid is closed (which lid can hinge, rotate or slide with respect to the chamber), there is little loss of pressure medium, which is advantageous in particular when relatively small volumes of pressure medium under high pressure are used. 
Kao rezultat brzog i pouzdanog priključka tlačnog odvoda, s jedne strane, CO, patrone, i, s druge strane, komore s HR P20070382 T3 pićem kad je poklopac zatvoren (poklopac se može zakretati ili kliziti u odnosu na komoru), vrelo je mali gubitak medija pod tlakom, što je naročito povoljno kad se koriste male količine tlačnog medija pod visokim pritiskom.
partially unsaturated, fully unsaturated); "alkenyl", as used herein, pertains to an alkyl group having one or more carbon-carbon double bonds; "alkynyl", as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds; 
djelomično nezasićen, potpuno nezasićen); "alkenil", kako se ovdje koristi, odnosi se na alkilnu skupinu koja ima jednu ili više dvostrukih veza ugljik-ugljik; "alkinil", kako se ovdje koristi, odnosi se na alkilnu skupinu koja ima jednu ili više trostrukih veza ugljik-ugljik;
Sanding element according to any one of claims I to 10, characterised in that the thickness of said compressible lamellas (4) is at least equal to three times the thickness of said sanding lamellas (3). 
Element za brušenje u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time, što je debljina navedenih lamela koje se mogu komprimirati (4) najmanje jednaka trostrukoj debljini lamela za brušenje (3).
Device, according to claim 4, characterised in that the synchronisation is carried out by transmitting a sequence of pulses, with at least two different signal durations. 
Mehanizam prema zahtjevu 4, naznačen time da se sinkronizacija vrši slanjem niza infracrvenih impulsa s najmanje dva različita trajanja signala.
is selected from the group consisting of C1-6 alkyl, substituted C1-6 alkyl, C2-6 alkenyl, substituted C2-6 alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycle, substituted heterocycle, cycloalkyl, substituted cycloalkyl, cycloalkenyl and substituted cycloalkenyl; 
je odabran iz skupine koju čine C1-6-alkil, supstituirani C1-6-alkil, C2-6-alkenil, supstituirani C2-6-alkenil, aril, supstituirani aril, heteroaril, supstiruirani heteroaril, heterocikl, supstituirani heterocikl, cikloalkil, supstituirani cikloalkil, cikloalkenil i supstituirani cikloalkenil;
An isolated nucleic acid comprising a sequence encoding an antibody or antigen binding fragment thereof that binds to human CEACAM5 protein, wherein said antibody or antigen binding fragment thereof comprises a CDR1-H comprising an amino acid sequence of SEQ ID NO:7, a CDR2-H comprising an amino acid sequence of SEQ ID NO:8, a CDR3-H comprising an amino acid sequence of SEQ ID NO:9, a CDR1-L comprising an amino acid sequence of SEQ ID NO:10, a CDR2-L comprising an amino acid sequence of NTR or an amino acid sequence of NTK, and a CDR3-L comprising an amino acid sequence of SEQ ID NO:12. 
Protutijelo koje sadrži teški lanac i laki lanac naznačeno time što varijabilna domena teškog lanca sadrži sekvencu SEQ ID NO: 5, ili sekvencu koja je najmanje 85% identična s njom, CDR1-H od sekvence SEQ ID NO:7, CDR2-H od sekvence SEQ ID NO:8, i CDR3-H od sekvence SEQ ID NO:9, te varijabilna domena lakog lanca sadrži sekvencu SEQ ID NO: 29, ili sekvencu koja je najmanje 85% identična s njom, CDR1-L od sekvence SEQ ID NO:10, CDR2-L od sekvence NTR i CDR3-L od sekvence SEQ ID NO:12.
The method of claim 1, wherein the endogenous mouse Vλ gene segments of the second endogenous Vλ-Jλ-Cλ gene cluster have been replaced with a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ3-27 gene segment to a human Vλ3-1 gene segment and a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ5-52 gene segment to a human Vλ1-40 gene segment. 
Miš prema patentnom zahtjevu 1, naznačen time, što miš sadrži: od 12 do 40 nepreuređenih segmenata gena varijabilne regije humanog imunoglobulinskog lakog lanca A (hV2) i najmanje jedan humani segment gena JA (hJA); 1 humanu međugensku sekvencu nukleinske kiseline VK-JK smještenu između 12 do 40 segmenata gena varijabilne regije humanog imunoglobulinskog lakog lanca i najmanje jedne sekvence nukleinske kiseline JA.
The method of item 1 for producing a disintegrin-like and metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13) protein in a continuous cell culture, the method comprising (a) culturing non-anchorage dependent mammalian cells expressing recombinant ADAMTS13 protein in a continuous cell culture system, where the cell culture system comprises a cell retention device having a cell retention rate of less than 90% and has a dilution rate (D) between 0.1 and 1.0 d-1 and a cell density of less than 1 X 107 cell/mL; and (b) recovering the ADAMTS13 protein from medium removed from the cell culture system. 
(a) kultiviranje stanica sisavaca koje eksprimiraju polipeptid u kontinuiranom sustavu stanične kulture, pri čemu navedeni sustav stanične kulture sadrži uređaj za zadržavanje stanica 1 ima stupanj razrjeđenja (D) od manje od 2 d"' i gustoću stanica od manje od 2 X 10 " stanica/mL; i (b) obnavljanje navedenog polipeptida iz medija uklonjenog iz navedenog sustava stanične kulture; pri čemu su navedene stanice genetički modificirane kako bi eksprimirale sličan disintegrinu i metalopeptidaza s trombospondinom tip 1 motiv 13 (ADAMTS13) protein.